PMID- 33346480 OWN - NLM STAT- MEDLINE DCOM- 20201222 LR - 20221207 IS - 0040-3660 (Print) IS - 0040-3660 (Linking) VI - 92 IP - 10 DP - 2020 Nov 24 TI - [The pharmacogenetics of hypoglycemia and the glycemic variability at the patients ith type 2 diabetes mellitus]. PG - 54-62 LID - 10.26442/00403660.2020.10.000530 [doi] AB - AIM: To investigate the link between the hypoglycemia (registrated accurately by the professional Continuous Glucose Monitoring CGM; severe hypoglycemia at home) and the hetero-/homozygote carriage of single nucleotide polymorphisms (SNP) of cytochrome systems geneCYP2C9(rs1799853CYP2C9*2 small i, Cyrillicrs1057910CYP2C9*3) at the patients with Type 2 Diabetes Mellitus (T2DM) used sulphonylurea (SU). MATERIALS AND METHODS: In Study Case-Control 120 T2DM-SU-patients genotyped by SNPs of geneCYP2C9(using PCR-RT) had been done the professional CGM (System iPro2, Medtronic) recorded Time in Range of Hypoglycemia (TIR-HYPO), level of Minimal CGM-hypoglycemia (MinGl) and standard CGM-parameters of Glycemic Variability. Severe hypoglycemia at home was recorded from visit to visit. The odds ratio (OR) of metabolic disturbances had been assessed for carriage SNPs in comparison with wide alleles. RESULTS: The Study established that carriage of SNPsrs1799853andrs1057910geneCYP2C9at T2DM-SU-patients associated with rising of Glycemic Variability and frequency of CGM-hypoglycemia (MinGl decreasing, increasing of TIR-HYPO and number of Glycemia Excursion 4 mmol/L/h), as well as increasing severe hypoglycemia at home (p0.05). Thus, OR at the carriage ofrs1799853andrs1057910respectively equaled: for CGM-hypoglycemia 7.78 (3.0220.01) and 5.80 (0.23145.87); number of Glycemia Excursion 4 mmol/L/h 5.76 (2.2914.43) and 4.44 (1.4313.76); MinGl3.9 mmol/L 4.39 (1.7910.75) and 6.26 (1.8421.30); CV40% (vs30%) 3.63 (1.0412.62) and 15.22 (0.59393.94);p0.05. CONCLUSION: At the real clinical practice the assessment of carriage of SNPs of geneCYP2C9before inclusion of SU to glucose-lowering scheme of T2DM-therapy it necessary to carry out for the detecting patients with a higher risk of hypoglycemia and rising of Glycemic Variability. FAU - Chernikova, N A AU - Chernikova NA AUID- ORCID: 0000-0002-0562-8396 AD - Russian Medical Academy of Continuous Professional Education. FAU - Kamynina, L L AU - Kamynina LL AUID- ORCID: 0000-0003-1217-545X AD - Russian Medical Academy of Continuous Professional Education. FAU - Ametov, A S AU - Ametov AS AUID- ORCID: 0000-0002-7936-7619 AD - Russian Medical Academy of Continuous Professional Education. FAU - Sychev, D A AU - Sychev DA AUID- ORCID: 0000-0002-4496-3680 AD - Russian Medical Academy of Continuous Professional Education. FAU - Grishina, E A AU - Grishina EA AUID- ORCID: 0000-0002-5621-8266 AD - Russian Medical Academy of Continuous Professional Education. FAU - Ryzhikova, K A AU - Ryzhikova KA AUID- ORCID: 0000-0003-3505-8520 AD - Russian Medical Academy of Continuous Professional Education. LA - rus PT - Journal Article DEP - 20201124 PL - Russia (Federation) TA - Ter Arkh JT - Terapevticheskii arkhiv JID - 2984818R RN - 0 (Blood Glucose) RN - 0 (Glycated Hemoglobin A) RN - 0 (Hypoglycemic Agents) SB - IM MH - Blood Glucose/metabolism MH - Blood Glucose Self-Monitoring MH - *Diabetes Mellitus, Type 2/drug therapy/genetics MH - Glycated Hemoglobin/analysis MH - Humans MH - *Hypoglycemia/chemically induced/genetics MH - Hypoglycemic Agents/*adverse effects/therapeutic use MH - Pharmacogenetics OTO - NOTNLM OT - CGM (Continuous Glucose Monitoring) OT - CYP2C9 OT - SNP (single nucleotide polymorphism) OT - genetics OT - glycemic variability OT - hypoglycemia OT - pharmacogenetics OT - type 2 diabetes mellitus EDAT- 2020/12/22 06:00 MHDA- 2020/12/23 06:00 CRDT- 2020/12/21 08:47 PHST- 2020/11/23 00:00 [received] PHST- 2020/11/23 00:00 [accepted] PHST- 2020/12/21 08:47 [entrez] PHST- 2020/12/22 06:00 [pubmed] PHST- 2020/12/23 06:00 [medline] AID - 10.26442/00403660.2020.10.000530 [doi] PST - epublish SO - Ter Arkh. 2020 Nov 24;92(10):54-62. doi: 10.26442/00403660.2020.10.000530.